Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10126	AZD7624
BP10126	AZD7624 is an p38 inhibitor. It has potent anti-inflammatory activity.
BP10015	AZD-8055
BP10015	AZD8055 is an ATP-competitive mTOR inhibitor (IC50: 0.8 nM in MDA-MB-468 cells). It is ~1,000-fold selective for mTOR over all PI3K isoforms.
BP10221	AZD8931 diFuMaric acid
BP10221	AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).
BP10914	Bakkenolide A
BP10914	Bakkenolide A has antifeedant and growth inhibitory effects on neonate variegated cutworms, it inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
BP10989	BAM 15
BP10989	BAM 15 is an uncoupler of mitochondrial protonophore.
BP10161	Baohuoside I
BP10161	Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
BP10018	B-AP15
BP10018	B-AP15(NSC687852) is a selective inhibitor of the deubiquitinating enzymes Usp14 and UCHL5 of the 26S proteasome. It blocks the deubiquitinating activity of the 26S proteasome.
BP10211	Baricitinib
BP10211	Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
BP10212	Baricitinib phosphate
BP10212	Baricitinib phosphate is a selective orally bioavailable JAK1/JAK2 inhibitor.
BP10904	Batabulin
BP10904	Batabulin is an antitumor compound, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induce apoptotic cell death.
BP10902	BAY 11-7082
BP10902	BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
BP10909	Bay 11-7085
BP10909	BAY 11-7085 can irreversibly inhibit the IκBα phosphorylation induced by TNFα (IC50: 10 μM).
BP10261	BAY 87-2243
BP10261	BAY 87-2243 is a potent and selective inhibitor of hypoxia-inducible factor-1 (HIF-1).
BP10443	BAY1082439
BP10443	BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth and it is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA.
BP10601	BC-1258
BP10601	BC-1258 is a unique small molecule F-box/LRR-repeat protein 2 (FBXL2) activator.
BP10858	BCR-ABL-IN-1
BP10858	BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
BP10869	BDA-366
BP10869	BDA-366 is a potent Bcl2 antagonist, binding Bcl2-BH4 domain with high affinity and selectivity (Ki = 3.3 nM). BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells.
BP10831	Befotertinib
BP10831	Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
BP10415	Belizatinib
BP10415	Belizatinib is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.
BP10728	Belzutifan
BP10728	PT2977 is a potential treatment for clear cell renal cell carcinoma (ccRCC). PT2977 is an orally active and selective HIF-2α inhibitor (IC50: 9 nM). PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile.